NEUROBLASTOMA UK
FIGHTING CHILDHOOD CANCER

NEUROBLASTOMA UK

Charity Commission reference number: 326385

REPORTS AND FINANCIAL STATEMENTS

For the year ended 31 December, 2025

REPORT AND FINANCIAL STATEMENTS
For the year ended 31 December, 2025

CONTENTS

	Page
Trustees' annual report	2-5
Independent Examiner's Report	6
Statement of Financial Activities	7
Balance sheet	8
Notes to the financial statements	9-12

TRUSTEES' ANNUAL REPORT for the year to 31 December, 2025

The Trustees present their report with the financial statements of the Charity for the year ended 31 December, 2025. The Trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015). As a charity registered in England and Wales, the Charity also reports in accordance with the Charity Commission for England and Wales' guidance on public benefit and the Charities Act 2015.

Section A Reference and administrative details

Charity Name	NEUROBLASTOMA UK
Registered Charity Number	326385
Registered Address	Canopi, 82 Tanner Street, London SE1 3GN

Trustees who manage the Charity:

Zara Aitchison (Co-Chair)
Tori Eadington (Secretary)
Malcolm Dean (Treasurer)
Clair Cliff (Treasurer)
Ruby Dickens
Stephen Smith
DeborahTweddle
Faye Watts
Kate Wheeler (Co-Chair)
Martin Elliott

Independent Examiner	DJH Liverpool Limited, Statutory Auditor, 3rd Floor Pacific Chambers, 11-13 Victoria Street, Liverpool, L2 5QQ
Bankers	Barclays Bank PLC, Newmarket, LE87 2BB

Public Benefit Requirement

The trustees of Neuroblastoma UK confirm that they have complied with their duty to have due regard to the guidance on public benefit published by the Charity Commission in exercising their powers or duties.

Section B Structure, governance and management

Governing Document

The Trust is an unincorporated trust, constituted under a Trust Deed dated 20 May, 1983 and by the supplemental Deed of Amendment 9th September 2016 and is a registered Charity number 326385 in England and Wales.

Recruitment and appointment of new trustees

Lay Trustees are appointed by the Trustees following consideration of applications received from individuals. Medical Trustees are appointed by the Trustees on the recommendation of existing Medical Trustees.

Risk Management

Trustees have considered the major risks to which the Charity may be exposed; have reviewed them and established systems and procedures to manage them. Trustees consider the possibility that money placed on investment could be at risk if the organisation holding the deposit should fail. Although current investments are placed with large, well-established financial institutions Trustees identified the need to re-examine investment policy and have concluded that investments should be spread across a number of institutions to minimise the

impact if a single fund-holder should fail. The Trust is essentially a cash based charity, holding no property. The Charity has developed sufficient internal controls to monitor and minimise the risk of misappropriation of funds.

Section C Objectives and activities

Objectives and Aims

The object of the Charity is to improve treatments and outcomes for all children suffering with neuroblastoma, and to achieve this we raise funds for vital medical research. The Charity also raises awareness of the disease, advocates for improved accessibility to treatments and provides information and support to families.

Policy on Grant-Making

Trustees invite applications for grant awards by public advertisement, typically on the Charity's website. Normally this is biennially so that sufficient funds are available to commission meaningful research studies, although exceptions are occasionally made when judged appropriate by the Trustees in consultation with the Charity's Scientific Advisory Board (SAB). Applications are first considered by the Charity's SAB, which is made up of 5 scientists experienced in Neuroblastoma research and a chairman who is a paediatric oncology clinician. Each application is accompanied by reports from 2 or 3 referees who have specialist knowledge of the research area proposed, and by a response from the applicants to those reports. The SAB then recommends to Trustees applications worthy of grant funding in order of merit. Trustees award grants in the light of the SAB's advice and funds available. Grants are only awarded to the extent that resources have already accrued in the Charity's unrestricted fund or appropriate restricted fund.

Section D Achievements and performance

Charitable Activities

2024 was a year of significant spend for the Charity after hosting the Neuroblastoma UK Symposium and funding in excess of £1.1m in new research studies for Neuroblastoma.

The objective for 2025 was to replenish funds whilst continuing to advocate on behalf of the neuroblastoma community, raise awareness and fund small innovation studies whilst building up our reserves for the next major grant round which we hope will be in 2027.

We are delighted that our major research studies that were awarded at the end of 2024 , have all commenced during 2025 and will continue over the next 2-4 years . We received a grant to put towards our commitment to Professor Archibald's study at KCL in improvements in PET imaging of £125,000 (£62,500 in 20025 and the rest we should receive in 2026 YOA) from Solving Kids' Cancer UK supported by funding from Children with Cancer UK.

We rebranded our 'Small Grants' as 'Innovation Grants' to reflect the inspiring novel applications that we receive, which often test bold new ideas. These grants, although small, have shown significant impact and often act as ' proof of principle' research that can pave the way for larger clinical studies. We awarded funding for 3 new studies in 2025.
(£2,000 to the ICR to investigate better drug combination strategies for high risk neuroblastoma.Using advanced 3D tumour models to test combinations of ALK-blocking drugs with ATR inhibitors to see which are the most effective against chemotherapy resistant tumours.
£4,970 to University of Southampton to investigate boosting immune cell therapies for neuroblastoma which could strengthen future immunotherapy approaches.
We were grateful for support from the Grocers Charity of £5,000 which funded Dr Wang's research also at Southampton. This team of researchers recently discovered three sub groups within neuroblastoma that do not have MYCN amplification and this grant enabled them to look into potential new treatments for these sub groups.)

Also in 2025 , we committed funding to support the BIOPORTAL project in excess of £25,000 - the first UK data repository for children with neuroblastoma
.A new edition of our free "Parents Guide to Neuroblastoma" and our factsheet "Treatment options for relapsed or refractory high risk neuroblastoma", online and in print, in collaboration with Children's Cancer and Leukaemia Group and Solving Kids Cancer UK , was released.

From an advocacy perspective we supported the Rare Cancer Bill and are delighted that it has now been given the final approval by the House of Lords. This calls for a look at urgent disparities in care , research and survival outcomes of cancers that are perceived as 'rare'.
We continue to advocate as part of a collective voice with Cancer 52 and One Cancer Voice. Neuroblastoma UK were proud to present alongside 60 other charities a bold, fully funded National Cancer Plan to Downing Street.

This year we restructured our staffing as a small functional unit with a new management position. Along with most charities, we have not been adverse to the tougher economic environment of the last few years and we hope that this new structure will improve our fundraising margins through a clear focus on financial targets and a strengthened strategic brand management .

Our principal funding sources are voluntary donations and 2025 saw fundraising challenges from all over the British Isles from Kiltwalkers in Glasgow to coastal runs in Bournemouth and Co Antrim and past the sights in London, Birmingham and more.The Three Peaks have been climbed, 100km covered via bike,skydives completed, ball room dances, santa runs etc. 89 supporters took part in our '100 Miles in September' Challenge Comedy nights, bake sales and TedFest - our supporters have pulled out all the stops to raise funds on our behalf.
We are also grateful to major donations from the John Black Foundation, Robert Luff Foundation and the Peter John Foord Charitable Trust.

Significant fundraising events for us were the BBC Lifeline Appeal in January and February which aired on BBC1 and the Big Give Christmas Challenge with thanks to Georgia's Fund and Candis Publications.

The major event of the year for the neuroblastoma community was the final of 'Celebrity Traitors' watched by over 12 million and won by our own patron, Alan Carr. Not only did this mean that we were the receiver of the prize pot but over 137,000 people hit our website that night and 'neuroblastoma' was highlighted across the media. Whilst Alan won playing a dastardly Traitor , he is forever faithful to our Cause.

The Trustees express their gratitude to ALL partners , sponsors , volunteers, families and supporters whose amazing contributions have enabled Neuroblastoma UK to sustain and expand its work during the year. We remain faithful to finding a cure for neuroblastoma.

Section E Financial review

Reserves Policy

The annual income generated by the Charity is to be applied for charitable purposes in accordance with the Trust's objective. Year on year the trustees intend to make a full distribution of available income, subject to making adequate reserves for known and potential liabilities and commitments, where applicable. Any amounts not so distributed are accumulated in the unrestricted fund. Funds committed to supporting approved research, but not immediately required are invested in line with the investment policy described below. The balance held as unrestricted reserves at 31 December, 2025 was £105,777 (2024: (£295,947)) and Trustees have agreed that £70,000 of reserves must be held (over and above the grant commitments) to support 6 months of operational expenditure.

Investment Policy

The Trustees' intention is to maintain funds so that they are readily accessible when required, but are earning a reasonable return whilst not utilised.Trustees reviewed this policy in February 2005 and confirmed their policy of only placing funds in investments where the book value of the principal is maintained.

Statement of Trustees Responsibilities

The trustees are responsible for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity Law requires the trustees to prepare financial statements for each financial year. Under that law the trustees have elected to prepare the financial statements in accordance with the United Kingdom generally accepted accounting practice (United Kingdom Accounting Standards, comprising FRS 102 'The financial reporting standard applicable in the UK and Republic of Ireland', and applicable law).The financial statements are required by law to give a true and fair view of the state of affairs of the charity and of the surplus or deficit of the charity for that period. In preparing those financial statements the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP (FRS102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Charity will continue in business.

The Trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy the financial position of the Charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed.

They are also responsible for safeguarding the assets of the Charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on their behalf and with their approval by:

MRS Z AITCHISON
Chair

MS CLAIR CLIFF
Trustee and Treasurer

Independent Examiner's Report to the Trustees of Neuroblastoma UK

I report to the trustees on the examination of the accounts of Neuroblastoma UK for the year ended 31 December, 2025..

Respective Responsibilities of Trustees and Examiner

The Charity's trustees are responsible for the preparation of accounts in accordance with the requirements of the Charities Act 2011.

I have reported in respect of the examination of the Charity's accounts carried out under section 145 of the 2011 Act and in carrying out the examination have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the Act.

Independent Examiner's Statement

The Charity's gross income exceeded £250,000 and I am qualified to undertake the examination by being a qualified member of ICAEW.

I have completed the examination and can confirm that no material matters have come to my attention in connection with the examination, which gives me reasonable cause to believe that in, any material respect:

- the accounting records were not kept in accordance with section 130 of the Charities Act 2011;
- the accounts did not accord with the accounting records; or
- the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

Mr M J Forshaw BA FCA
DJH Liverpool Limited
Pacific Chambers
11-13 Victoria Street
Liverpool
L2 5QQ

NEUROBLASTOMA UK

STATEMENT OF FINANCIAL ACTIVITIES

YEAR ENDED 31 DECEMBER, 2025

	Note	Unrestricted Funds 31 December, 2025 £	£	Unrestricted Funds 31 December, 2024 £	£
INCOME AND ENDOWMENTS FROM:					
Donations	2		393,910		209,846
Other trading activities	3		52,628		46,985
Income from investments	4		44,459		46,519
TOTAL			**490,997**		303,350
EXPENDITURE ON:					
Raising funds	5	(1,717)		(464)	
Charitable activities:					
Grants payable and grant amendments	6	29,178		(1,012,496)	
Governance costs	7	(116,734)		(172,385)	
TOTAL			**(89,273)**		(1,185,345)
NET INCOME/(EXPENDITURE)			**401,724**		(881,995)
RECONCILIATION OF FUNDS					
Total funds brought forward			(295,947)		586,048
TOTAL FUNDS CARRIED FORWARD			**105,777**		(295,947)

NEUROBLASTOMA UK

BALANCE SHEET

AS AT 31 DECEMBER, 2025

	Note	2025 £	2024 £
CURRENT ASSETS			
Debtors and advance payments	9	17,730	24,664
Investments	10	1,083,649	1,250,792
Cash at bank	11	260,530	100,743
TOTAL CURRENT ASSETS		1,361,909	1,376,198
CREDITORS: Amounts falling due within one year	12	(346,170)	(483,564)
NET CURRENT ASSETS		1,015,739	892,634
CREDITORS: Amounts falling due in more than one year	13	(909,962)	(1,188,581)
NET ASSETS		**105,777**	(295,947)
FUNDS OF THE CHARITY			
Unrestricted fund	15	**105,777**	(295,947)

The financial statements set out on pages 8 – 13 were approved by the Trustees on 23rd of July 26:

TRUSTEE – Mrs Z Aitchison

TRUSTEE – MS C Clair

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charitable trust, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS102) (effective 1 January, 2015)', the Financial Reporting Standard 102 (effective January 2015) and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Donations

Cash donations and gifts are included in full in the Statement of Financial Activities when they are received by the Charity. Cash collected at special fund-raising events is included in the income and expenditure account after deducting the expenditure incurred directly in staging the event. Significant non-cash donations are included in the income and expenditure account at the Trustees' estimation of their market value when received.

Income from investments

Investment income is included in the Statement of Financial Activities on an accruals basis.

Research grant awards

These are charged to the Statement of Financial Activities when the Trustees have awarded them. Research grants awarded, but not disbursed at the balance sheet date, are carried forward as grant creditors in the balance sheet.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund Is included in the notes to the financial statements.

Cash flow statements

The Charity has taken advantage of the exemption provided by the Charities SORP (FRS102) and does not prepare a cash flow statement.

Taxation

The Charity is exempt from taxation on its charitable activities.

VAT

As a non-trading organisation, the Charity is not registered for VAT purposes and is unable to recover VAT incurred on its expenditure.

2. DONATIONS

	2025	2024
	£	£
Donations and fund-raising	393,910	209,846

3. OTHER TRADING ACTIVITIES

	2025	2024
	£	£
Christmas cards, webshop and other income	52,628	46,985

4. INCOME FROM INVESTMENTS

	2025	2024
	£	£
COIF deposit	32,857	33,315
National savings income bonds	11,601	12,204
	44,459	46,519

5. EXPENDITURE ON RAISING FUNDS

	2025	2024
	£	£
Fund-raising and publicity costs	1,717	464

6. GRANTS PAYABLE AND GRANT AMENDMENTS

	2025	2024
	£	£
Contribution from Medical Research Council		(89,857)
Archibald	(62,500)	268,301
Chesler		254,120
Falconer		188,039
Piskareva		208,887
Stoker		183,207
Written Off		
Small Grants	33,322	(201)
	(29,178)	1,012,496

7. EXPENDITURE ON CHARITABLE ACTIVITIES

	2025 £	2024 £
Rent and facilities	8,310	8,573
Cambridge Symposium	0	38,893
Staff salaries and pension contributions	76,775	96,012
Sporting event costs	6,988	5,407
Subscriptions	2,344	4,734
Travel	20	0
Computers, software and equipment hire	6,212	9,027
Accounts and audit	840	840
Trustees meeting costs	0	714
Printing, postage and stationery	1,003	262
Legal fees	0	1,869
Sundries	919	1,926
Advertising and website	2,787	1,944
Insurance	1,226	1,202
Bank and professional charges	9,310	982
	116,734	172,385

8. TRUSTEES' REMUNERATION AND BENEFITS

There was no trustees' remuneration or other benefits for the year ended 31 December, 2025 (2024: £NIL).

The Trust owns no premises.

9. DEBTORS AND PREPAYMENTS

	2025	2024
	£	£
Receivables	1,188	1,188
Prepayments	2,292	4,226
Co-funding income	14,250	19,250
	17,730	24,663

10. CURRENT INVESTMENTS

11. CASH AT BANK AND IN HAND

	2025	2024
	£	£
Cash at Bank	260,530	100,742

12. CREDITORS – DUE WITHIN ONE YEAR

	2025	2024
	£	£
Grant commitments	300,654	465,696
Trade creditors	4,202	1,966
Accruals	26,314	900
Co-funding income received in advance	15,000	15,000
	346,170	483,562

13. CREDITORS – DUE IN MORE THAN ONE YEAR

	2025	2024
	£	£
Grant commitments	909,962	1,188,581

14. GRANT COMMITMENTS

	2025	2024
	£	£
Total commitments at 1 January, 2025	1,654,479	670,328
Paid in the year	(450,804)	(118,403)
New commitments	7,142	1,102,554
	1,210,817	1,654,479

All of the new grant commitments are to institutions.

15. ANALYSIS OF UNRESTRICTED FUND

	2025	2024
	£	£
At 1 January, 2024	(295,947)	586,048
Net movement in funds for the year	401,724	(881,995)
	105,777	(295,947)